The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition

Biochemical Pharmacology

Volumn 74, Issue 10, 2007, Pages 1496-1506

  Bailón, Elvira ^a   Camuesco, Desirée ^a   Nieto, Ana ^b   Concha, Angel ^c   Arriba, Alberto Fernández de ^d   Román, Juan ^d   Ramis, Isabel ^d   Merlos, Manuel ^d   Zarzuelo, Antonio ^a   Gálvez, Julio ^a   Comalada, Mònica ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Health and Progress Foundation   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d Palau Pharma SA   (Spain)

Author keywords

Crohn's disease; Cyclosporine A; Inflammatory bowel disease; Lymphocyte; Salicylates; Th1 inflammation

Indexed keywords

(2 HYDROXY 4 (2,2,3,3,3 PENTAFLUOROPROPOXY) BENZOIC ACID); 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CONCANAVALIN A; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; LEUKOTRIENE B4; SALICYLIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UR 1505;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL INFILTRATION; CELL PROLIFERATION; CELL VIABILITY; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; GENETIC SUSCEPTIBILITY; IMMUNOCOMPETENT CELL; IMMUNOHISTOLOGY; IN VITRO STUDY; LEUKOCYTE; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; COLITIS; COLON; CROHN DISEASE; DISEASE MODELS, ANIMAL; FEMALE; GLUTATHIONE; INTERFERON TYPE II; LEUKOTRIENE B4; MACROPHAGES; MICE; MICE, INBRED BALB C; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, WISTAR; SALICYLIC ACIDS; SPLEEN; T-LYMPHOCYTES; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35348902519     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.07.026     Document Type: Article

References (40)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
2. Nielsen O.H., and Rask-Madsen J. Mediators of inflammation in chronic inflammatory bowel disease. Scand J Gastroenterol Suppl 216 (1996) 149-159
3. Katz J.A., Itoh J., and Fiocchi C. Pathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol 15 (1999) 291-297
4. Strober W., Fuss I.J., Ehrhardt R.O., Neurath M., Boirivant M., and Ludviksson B.R. Mucosal immunoregulation and inflammatory bowel disease: new insights from murine models of inflammation. Scand J Immunol 48 (1998) 453-458
5. Strober W., Fuss I.J., and Blumberg R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 20 (2002) 495-549
6. Fuss I.J., Neurath M., Boirivant M., Klein J.S., de la Motte C., Strong S.A., et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157 (1996) 1261-1270
7. Monteleone G., Biancone L., Marasco R., Morrone G., Marasco O., Luzza F., et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112 (1997) 1169-1178
8. Hanauer S.B. Medical therapy for ulcerative colitis 2004. Gastroenterology 126 (2004) 1582-1592
9. Holtmann M.H., Galle P.R., and Neurath M.F. Immunotherapeutic approaches to inflammatory bowel diseases. Expert Opin Biol Ther 1 (2001) 455-466
10. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999) 761-769
11. Egan L.J., and Sandborn W.J. Drug therapy of inflammatory bowel disease. Drugs Today (Barc) 34 (1998) 431-446
12. Matasic R., Dietz A.B., and Vuk-Pavlovic S. Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology 101 (2000) 53-60
13. Paccani S.R., Boncristiano M., Ulivieri C., D'Elios M.M., Del Prete G., and Baldari C.T. Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction. J Biol Chem 277 (2002) 1509-1513
14. Kim H., Jeon H., Kong H., Yang Y., Choi B., Kim Y.M., et al. A molecular mechanism for the anti-inflammatory effect of taurine-conjugated 5-aminosalicylic acid in inflamed colon. Mol Pharmacol 69 (2006) 1405-1412
15. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., and Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96 (1989) 795-803
16. Camuesco D., Peran L., Comalada M., Nieto A., Di Stasi L.C., Rodriguez-Cabezas M.E., et al. Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis. Inflamm Bowel Dis 11 (2005) 265-271
17. Lara-Villoslada F., de Haro O., Camuesco D., Comalada M., Velasco J., Zarzuelo A., et al. Short-chain fructooligosaccharides, in spite of being fermented in the upper part of the large intestine, have anti-inflammatory activity in the TNBS model of colitis. Eur J Nutr 45 (2006) 418-425
18. Bell C.J., Gall D.G., and Wallace J.L. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol 268 (1995) G622-G630
19. Krawisz J.E., Sharon P., and Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87 (1984) 1344-1350
20. Anderson M.E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 113 (1985) 548-555
21. Xaus J., Besalduch N., Comalada M., Marcoval J., Pujol R., Mana J., et al. High expression of p21Waf1 in sarcoid granulomas: a putative role for long-lasting inflammation. J Leukoc Biol 74 (2003) 295-301
22. Comalada M., Ballester I., Bailon E., Sierra S., Xaus J., Galvez J., et al. Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: analysis of the structure-activity relationship. Biochem Pharmacol 72 (2006) 1010-1021
23. Comalada M., Valledor A.F., Sanchez-Tillo E., Umbert I., Xaus J., and Celada A. Macrophage colony-stimulating factor-dependent macrophage proliferation is mediated through a calcineurin-independent but immunophilin-dependent mechanism that mediates the activation of external regulated kinases. Eur J Immunol 33 (2003) 3091-3100
24. Comalada M., Bailon E., de Haro O., Lara-Villoslada F., Xaus J., Zarzuelo A., et al. The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype. J Cancer Res Clin Oncol 132 (2006) 487-497
25. Camuesco D., Comalada M., Rodriguez-Cabezas M.E., Nieto A., Lorente M.D., Concha A., et al. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br J Pharmacol 143 (2004) 908-918
26. Comalada M., Camuesco D., Sierra S., Ballester I., Xaus J., Galvez J., et al. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits through down-regulation of the NF-kappaB pathway. Eur J Immunol 35 (2005) 584-592
27. Cavallini L., Francesconi M.A., Zoccarato F., and Alexandre A. Involvement of nuclear factor-kappa B (NF-kappaB) activation in mitogen-induced lymphocyte proliferation: inhibitory effects of lymphoproliferation by salicylates acting as NF-kappaB inhibitors. Biochem Pharmacol 62 (2001) 141-147
28. Redford T.W., Yi A.K., Ward C.T., and Krieg A.M. Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. J Immunol 161 (1998) 3930-3935
29. Arnott I.D., Watts D., and Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res 47 (2003) 1-10
30. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., and Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182 (1995) 1281-1290
31. Higgins L.M., McDonald S.A., Whittle N., Crockett N., Shields J.G., and MacDonald T.T. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol 162 (1999) 486-493
32. Garcia-Ramallo E., Marques T., Prats N., Beleta J., Kunkel S.L., and Godessart N. Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation. J Immunol 169 (2002) 6467-6473
33. Pavlick K.P., Laroux F.S., Fuseler J., Wolf R.E., Gray L., Hoffman J., et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 33 (2002) 311-322
34. Galvez J., Garrido M., Rodriguez-Cabezas M.E., Ramis I., de Medina F.S., Merlos M., et al. The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production. Inflamm Bowel Dis 9 (2003) 363-371
35. Van Deventer S.J. Tumor necrosis factor and Crohn's disease. Gut 40 (1997) 443-448
36. Salas A., Gironella M., Salas A., Soriano A., Sans M., Iovanna J., et al. Nitric oxide supplementation ameliorates dextran sulfate sodium-induced colitis in mice. Lab Invest 82 (2002) 597-607
37. Rachmilewitz D., Karmeli F., Okon E., and Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 37 (1995) 247-255
38. Celada A., Allen R., Esparza I., Gray P.W., and Schreiber R.D. Demonstration and partial characterization of the interferon-gamma receptor on human mononuclear phagocytes. J Clin Invest 76 (1985) 2196-2205
39. Gorham J.D., Guler M.L., and Murphy K.M. Genetic control of interleukin 12 responsiveness: implications for disease pathogenesis. J Mol Med 75 (1997) 502-511
40. Fukata M., Chen A., Klepper A., Krishnareddy S., Vmadevan A.S., thomas L.S., et al. COX-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 131 (2006) 862-877